摘要
目的测定肾移植受者干扰素γ、转化生长因子β1基因型,探讨在肾移植慢性排斥反应中,细胞因子与免疫抑制药物CsA之间的关系。方法用PCR方法,在肾移植前进行IFN-γ、TGF-β1基因型检测,追踪移植肾慢性排斥反应发生情况,分析受者基因型及免疫抑制药物不同组合对移植肾功能的影响。结果肾移植受者IFN-γ高分泌型+CsA中低剂量组慢性排斥反应的发生率较高,肾移植受者TGF-β1高+中分泌型+CsA中低剂量组慢性排斥反应的发生率较高。结论受者IFN-γ和TGF-β1基因分泌型与免疫抑制剂用量的某种组合与移植肾慢性排斥反应发生率有关联。
OBJECTIVE Testing the genotypes of interferon-γ（INF-γ） and transforming growth factor-β1 （TGF-β1 ）to study the relationship between cytokine genotypes and the immunosuppressive drug（ cyclosporine A） in chronic renal allograft rejection. METHODS The INF-γand TGF-β1 genotypes of 122 primary cadaveric renal allograft recipients were detected using PCR-SSP method before the transplantation. According to the CSA therapeutic dose the recipients were divided into three groups. The recipients were followed up for 3 years. Analyze the relationship between the recipients＇genotypes and different therapeutic doses in the chronic renal allograft rejection. RESULTS The rate of chronic renal allograft rejection in the recipients with INF-γ high producer genotype/ CsA mediate and low dosage[74.19% （23/31）] was significantly higher than that in those with the other INF-γ genotypes/CsA dosage[ 20. 88% （ 19/91 ） ] （P 〈 0. 01 ）. No significant difference was detected between the recipients with INF-γ low producer genotype/CsA high dosage [ 36. 36% （4/11 ） ] and those with INF-γ low producer genotypes/CsA mediate and low dosage[ 17.33% （13/75） ] （P 〉0. 05）. The rate of chronic renal allograft rejection in the recipients with TGF-β1 high producer genotype/CsA mediate and low dosage[60% （15/25）] was significantly higher than that in those with the other TGF-β1 genotypes/CsA dosage[ 27.84% （27/97） ] （P 〈0. 01 ）. No significant difference was detected between the recipients with TGF-β1 low producer genotype/CsA high dosage [43.75% （7/16） ] and those with TGF-β1 low producer genotypes/CsA mediate and low dosage [ 24.35 % （ 19/78 ）] （P 〉 0. 05）. CONCLUSION The combination of the INF-γ/and TGF-β1 genotypes and the CsA therapeutic dose in the recipients of renal transplantation have relationships with chronic renal allograft rejection. So the individualization of the immunosuppressive therapeutic dose can be decided by testing recipients＇cytokine genotype
出处
《海峡药学》
2007年第9期75-77,共3页
Strait Pharmaceutical Journal
关键词
细胞因子基因型
慢性排斥
环孢素A
Cytokine genotype
Intefferon-γ
Transforming growth factor-β1
Chronic renal aUograft rejection
Cyelosporine A
